AZ’s COVID-19 jab sales top $1.2bn, but come at a lossAstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in Share XAZ’s COVID-19 jab sales top $1.2bn, but come at a losshttps://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/
AstraZeneca bags Imfinzi okay in big Chinese lung cancer marketChina has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the Share XAstraZeneca bags Imfinzi okay in big Chinese lung cancer markethttps://pharmaphorum.com/news/astrazeneca-bags-imfinzi-okay-in-big-chinese-lung-cancer-market/
AZ withdraws Imfinzi in US bladder cancer use after trial failureAstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer Share XAZ withdraws Imfinzi in US bladder cancer use after trial failurehttps://pharmaphorum.com/news/az-withdraws-imfinzi-in-us-bladder-cancer-use-after-trial-setback/
AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerAfter a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi Share XAZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerhttps://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/
FDA approves AZ Imfinzi in new lung cancer useAstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, Share XFDA approves AZ Imfinzi in new lung cancer usehttps://pharmaphorum.com/news/fda-approves-az-imfinzi-in-new-lung-cancer-use/
AZ’s immunotherapy combo fails in phase 3 lung cancer trialAstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a Share XAZ’s immunotherapy combo fails in phase 3 lung cancer trialhttps://pharmaphorum.com/news/azs-immunotherapy-combo-fails-in-phase-3-lung-cancer-trial/
Finally, AZ claims a win with Imfinzi/tremelimumab cancer comboAstraZeneca’s development of checkpoint inhibitor combination Imfinzi and tremelimumab has chalked up serial trial failures in the last Share XFinally, AZ claims a win with Imfinzi/tremelimumab cancer combohttps://pharmaphorum.com/news/finally-az-claims-a-win-with-imfinzi-tremelimumab-cancer-combo/
AZ’s new cancer drugs drive another stellar quarterAstraZeneca has raised its sales guidance of the year once again as its trio of new cancer drugs Share XAZ’s new cancer drugs drive another stellar quarterhttps://pharmaphorum.com/news/azs-new-cancer-drugs-drive-another-stellar-quarter/
AstraZeneca cancer drugs approved in JapanAstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months Share XAstraZeneca cancer drugs approved in Japanhttps://pharmaphorum.com/r-d/astrazenecas-cancer-drugs-approved-japan/
